Cargando…
Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2
Outbreak of Coronavirus Disease 2019 (COVID-19) has become a great challenge for scientific community globally. Virus enters cell through spike glycoprotein fusion with ACE2 (Angiotensin-Converting Enzyme 2) human receptor. Hence, spike glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2...
Autores principales: | Rathod, Shravan B., Prajapati, Pravin B., Punjabi, Lata B., Prajapati, Kuntal N., Chauhan, Neha, Mansuri, Mohmedyasin F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649901/ https://www.ncbi.nlm.nih.gov/pubmed/33184600 http://dx.doi.org/10.1007/s40203-020-00055-w |
Ejemplares similares
-
A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD—ACE2 Interaction
por: Fernandez-Fuentes, Narcis, et al.
Publicado: (2021) -
Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2
por: Ojha, Rupal, et al.
Publicado: (2022) -
Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction
por: Eka Saputri, Meliana, et al.
Publicado: (2022) -
In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19
por: BR, Bharath, et al.
Publicado: (2020) -
The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
por: Semenov, Valentin A., et al.
Publicado: (2022)